Finance

Vaccine producer provides updates on corporate programs

Published in TB and Outbreaks Week, June 3rd, 2003

Acambis plc (ACAM) announced its results for the first quarter ended 31 March 2003.

[helv]During the first quarter of 2003, there were a number of positive developments relating to our smallpox vaccine franchise.

We are announcing further information on our contracts with the U.S. government and providing an update on contracts with other governments around the world. These are described in further detail below.

In February, we were awarded a $9.2m contract by the U.S. National Institutes of Allergy and Infectious Diseases (NIAID) relating to development of a new Modified Vaccinia Ankara (MVA) vaccine, which is a weakened form of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2003-06-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry